Novabay Reported Preliminary 2023 Sales Of $14.7M, Consisting Of $3.6M From Its DERMAdoctor Skincare Segment And $11.1M From Its Eyecare And Wound Care Segment Versus Consensus Of $14.40M
Novabay Reported Preliminary 2023 Sales Of $14.7M, Consisting Of $3.6M From Its DERMAdoctor Skincare Segment And $11.1M From Its Eyecare And Wound Care Segment Versus Consensus Of $14.40M
Novabay報告稱，2023年初步銷售額爲1470萬美元，其中包括來自其DermaDoctor護膚板塊的360萬美元和眼部護理和傷口護理板塊的1110萬美元，而預期銷售額爲1440萬美元
Operating loss for the 2023 fiscal year is expected to be approximately $7.4 million, which includes a $3.8 million loss in the DERMAdoctor skincare segment. The DERMAdoctor skincare segment loss includes a $2.5 million non-cash impairment of goodwill and indefinite lived and long-lived assets related to the business segment.
2023財年的營業虧損預計約爲740萬美元，其中包括DermaDoctor護膚板塊的380萬美元虧損。DermaDoctor護膚板塊的虧損包括250萬美元的非現金商譽減值以及與該業務板塊相關的無限期和長期資產。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。